Download MendeleyRedox Regulation of a Gain-of-Function Mutation (N308D) in SHP2 Noonan Syndrome.
Machado, L.E.S.F., Critton, D.A., Page, R., Peti, W.(2017) ACS Omega 2: 8313-8318
- PubMed: 29214238
- DOI: https://doi.org/10.1021/acsomega.7b01318
- Primary Citation of Related Structures:
6ATD - PubMed Abstract:
SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase 2; PTPN11) is a ubiquitous multidomain, nonreceptor protein tyrosine phosphatase (PTP) that plays an important role in diseases such as cancer, diabetes, and Noonan syndrome (NS). NS is one of the most common genetic disorders associated with congenital heart disease, and approximately half of the patients with Noonan syndrome have gain-of-function mutations in SHP2. One of the most common NS mutations is N308D. The activity of SHP2, like that of most PTPs, is reversibly inactivated by reactive oxygen species (ROS). However, the molecular basis of this inactivation and the consequences of NS-related mutations in PTPN11 on ROS-mediated inhibition are poorly understood. Here, we investigated the mechanistic and structural details of the reversible oxidation of the NS variant SHP2 N308D . We show that SHP2 N308D is more sensitive to oxidation when compared with wild-type SHP2. We also show that although the SHP2 N308D catalytic domain can be reactivated by dithiothreitol as effectively as the wild-type, full-length SHP2 N308D is only poorly reactivated by comparison. To understand the mechanism of oxidation at a molecular level, we determined the crystal structure of oxidized SHP2 N308D . The structure shows that the catalytic Cys459 residue forms a disulfide bond with Cys367, which confirms that Cys367 functions as the "backdoor" cysteine in SHP2. Together, our data suggest that the reversible oxidation of SHP2 contributes negligibly, if at all, to the symptoms associated with NS.
Organizational Affiliation:
Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721, United States.
